Form 4: Silence Therapeutics Director Richard Ian Griffiths Reports Significant Share Acquisitions

Director Richard Ian Griffiths reports multiple transactions involving the purchase of Silence Therapeutics plc American Depositary Shares (ADS) and ordinary shares.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions from January 8, 2025, to February 18, 2025.
• Griffiths directly and indirectly acquired American Depositary Shares (ADS) through Cream Capital Limited.
• The ADS are immediately convertible into three ordinary shares each.
• The transactions involved purchases at prices ranging from $4.17 to $6.48 per ADS.
• Griffiths' direct holdings increased to 9,478,667 ordinary shares, and indirect holdings through Cream Capital Limited increased to 9,325,893 ordinary shares.
• Griffiths disclaims beneficial ownership of shares held by Cream Capital Limited except to the extent of his proportionate pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a report of transactions, not necessarily indicative of positive or negative company performance. The director's purchases could be seen as a positive signal, but it's not definitive.

Positives

• The director's purchases may signal confidence in the company's future prospects.

Management Comments

• Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's securities, providing transparency to the market.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders in publicly traded companies, ensuring transparency and preventing insider trading.
• Similar filings are common across the pharmaceutical and biotechnology industries, where insider transactions are closely monitored due to the potential for significant price fluctuations based on clinical trial results and regulatory approvals.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which are also involved in RNAi therapeutics, would have similar insider transaction reporting requirements.

Stakeholder Impact

• Shareholders may view the director's purchases as a positive sign of confidence in the company's prospects.

Key Dates